Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0296728 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Claudia Cristina Jardim Duarte und 15 weiteren Autor:innen. Beteiligte Einrichtung: Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Ototoxicity, Tinnitus, Antiprotozoal Agents, Organometallic Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
American Tegumentary Leishmaniasis (ATL) treatment is based on pentavalent antimonials (Sb 5+ ), but these drugs have been associated to several adverse effects. Hearing loss and tinnitus during treatment with meglumine antimoniate (MA) have already been reported. This study aimed to describe the usefulness of self-reporting of hearing loss and tinnitus in diagnosing MA-induced ototoxicity.
Methods
A prospective longitudinal study was conducted with 102 patients with parasitological diagnosis of ATL, treated with different MA schemes. The presence of clinical auditory toxicity was defined as the emergence or worsening of self-reporting hearing loss and/or tinnitus during monitoring. Measures of sensitivity, specificity, and the positive and negative predictive value of the patient’s self-reporting of hearing loss and tinnitus in relation to the result of the audiometric test (considered the gold standard) were calculated.
Results
The age of the evaluated patients ranged from 15 to 81 years, with a median of 41 years, and most were male (73.5%). Seventy-five patients (73.5%) had cutaneous leishmaniasis and 27 (26.5%) mucosal leishmaniasis. Eighty-six patients (84.3%) received intramuscular (IM) treatment and 16 (15.7%) were treated with intralesional MA. During treatment, 18 (17,6%) had tinnitus and 7 (6,9%) had complaint of hearing loss. 53 (52%) patients had cochlear toxicity confirmed by tone threshold audiometry and high frequency audiometry, from which 60% received a dose of 20 mg Sb 5+ /kg/day (p = 0.015) and 96.2% were treated with IM MA (p = 0.001). Tinnitus has greater specificity and positive predictive value than hearing loss, with a low number of false positives, but with a high false negative value.
Conclusion
Although the large number of false negatives suggests that self-report of hearing loss or tinnitus cannot be considered a good screening test for referring the patient to an audiometry, the low number of false positives suggests the need to value the patient’s complaint for referral. Otherwise, this study reinforces the importance of audiological monitoring during treatment with MA, especially in those patients with self-reporting of hearing loss or tinnitus when treated with 20 mg Sb 5+ /kg/day via IM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
- Department of Otorhinolaryngology and Ophtalmology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Brazil´s navy, Rio de Janeiro, Brazil.
- Department of Otorhinolaringology, Federal University of the Estate of Rio de Janeiro, Rio de Janeiro, Brazil.
- Medicine School, Souza Marques Technical and Scientific Foundation, Rio de Janeiro, Brazil.
- Productivity fellowship holder of the Brazilian National Council for Scientific and Technological Development (CNPQ), Brasília, Brazil.
ORCID-Profile: Cláudia Maria Valete
Zitieren
APA
Duarte, C. C. J., Torraca, T. S. S., Bezerra, D. O., Oliveira, R. B., Leite, N. K. S., de Oliveira, R. V. C., Araújo-Melo, M. H., Pimentel, M. I. F., Costa, A. D. D., Vasconcellos, É. C. F., Lyra, M. R., Soares, E. C. D. A., Paes, L. R. D. N. B., Salgueiro, M. M., Schubach, A. O., & Valete, C. M. (2024). Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis. PLOS ONE. https://doi.org/10.1371/journal.pone.0296728
Vancouver
Duarte CCJ, Torraca TSS, Bezerra DO, Oliveira RB, Leite NKS, de Oliveira RVC, et al. Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis. PLOS ONE. 2024. doi:10.1371/journal.pone.0296728
BibTeX
@article{Duarte2024,
author = {Duarte, Claudia Cristina Jardim and Torraca, Tania Salgado de Sousa and Bezerra, Débora de Oliveira and Oliveira, Renata de Barcelos and Leite, Nayany Kerollyany Sousa and de Oliveira, Raquel de Vasconcellos Carvalhaes and Araújo-Melo, Maria Helena and Pimentel, Maria Inês Fernandes and Costa, Ananda Dutra da and Vasconcellos, Érica de Camargo Ferreira and Lyra, Marcelo Rosandiski and Soares, Ester Cleisla Dos Anjos and Paes, Lúcia Regina do Nascimento Brahim and Salgueiro, Mariza Mattos and Schubach, Armando de Oliveira and Valete, Cláudia Maria},
title = {Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0296728}
}
EUVIMED